The Korean stock market has been volatile recently, with the KOSPI index hovering just above 2,580 points after mixed performance influenced by global earnings reports and sector-specific movements. In this environment of uncertainty and growth potential, identifying high-growth tech stocks requires careful consideration of their adaptability to market dynamics and resilience in the face of broader economic challenges. There is a need.
name
increase in revenue
revenue growth
growth assessment
IML Co., Ltd.
21.80%
111.43%
★★★★★
Sojin System Co., Ltd.
33.39%
49.13%
★★★★★
frit
32.60%
106.82%
★★★★★
Bioneer
23.53%
97.58%
★★★★★
nexon games
27.44%
69.62%
★★★★★
arteogen
64.22%
99.46%
★★★★★
fat sisters
29.08%
63.02%
★★★★★
park system
22.96%
33.25%
★★★★★
AmoSense Co., Ltd.
24.04%
71.97%
★★★★★
urinary tract infection
114.97%
134.60%
★★★★★
Click here to see the complete list of 47 stocks on the KRX High Growth Technology and AI Stock Screener.
Here we highlight a subset of preferred stocks from the screener.
Simply Wall Street Growth Rating: ★★★★☆
Overview: YG Entertainment Inc. is an entertainment company with a market capitalization of 772.48 billion won, with operations in South Korea, Japan, and overseas.
Business Operations: The company mainly derives its revenue from the entertainment sector, which totals approximately 493.91 billion won.
YG Entertainment is in the midst of a difficult quarter in which it posted a significant net loss of 1,924.89 million won, up from 21.71977 billion won in net profit in the same period last year, but still projects solid future growth . Despite the recent drop in profits and sales (0.00003 million won this quarter compared to 0.00002 million won last year), the company showed an impressive 17.6% annual increase in sales and a It is predicted that there is a potential for a 65.4% annual jump compared to the same period last year. next 3 years. This optimistic outlook is supported by plans for a significant increase in R&D spending aimed at innovation in the entertainment sector, which has the potential to significantly improve the competitiveness and market position of the entertainment sector. there is.
KOSDAQ:A122870 Revenue and revenue growth as of October 2024
Simply Wall Street Growth Rating: ★★★★★☆
Overview: PharmaResearch Co., Ltd. is a biopharmaceutical company primarily operating in South Korea, with a market capitalization of 2.38 trillion won.
Business Operations: PharmaResearch, along with its subsidiaries, focuses on the biopharmaceutical sector in South Korea and generates revenue of 296.59 billion won, mainly from pharmaceuticals.
story continues
PharmaResearch, a South Korean biotechnology company, survives the competitive environment with strong R&D investments and strategic private placements. The company announced the issuance of over 1.17 million shares in 2024 at 170,119 won per share, raising nearly 200 billion won in proceeds aimed at strengthening its research capabilities. This capital injection is significant as PharmaResearch’s revenue is expected to grow by a significant 22.2% per year. Additionally, the company’s revenue growth forecast is notable at 22.3% per year, which is higher than the overall Korean market average of 10.3%. These numbers highlight our strategic focus on innovation and market expansion through significant reinvestment in research and development, essential to maintaining a competitive advantage in the rapidly evolving biotechnology sector. .
KOSDAQ:A214450 Breakdown of revenue and expenses as of October 2024
Simply Wall Street Growth Rating: ★★★★☆
Overview: HYBE Co., Ltd. is engaged in music production, publishing, artist development and management, and has a market capitalization of 8.08 trillion won.
Operations: The company primarily generates revenue through three segments: Labels, Platforms, and Solutions. The label division leads with 1.28 trillion won, followed by the solution division with 1.24 trillion won, and the platform division contributes 361.12 billion won to the revenue model.
South Korean entertainment conglomerate HYBE is showing strong growth, with revenue expected to increase by 42.5% annually. This performance exceeds the average industry growth rate of 7.3% and highlights HYBE’s competitive position in a dynamic market. Recently, the company has strategically used private placements and share buybacks to strengthen its financial stability and investor confidence. For example, in September 2024, it bought back 150,000 shares for 26 billion won. Additionally, HYBE’s commitment to innovation is evident in its significant research and development investments to sustain long-term growth in the fast-paced technology sector.
KOSE:A352820 Breakdown of revenue and expenses as of October 2024
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts using only unbiased methodologies, and articles are not intended to be financial advice. This is not a recommendation to buy or sell any stock, and does not take into account your objectives or financial situation. We aim to provide long-term, focused analysis based on fundamental data. Note that our analysis may not factor in the latest announcements or qualitative material from price-sensitive companies. Simply Wall St has no position in any stocks mentioned.
Companies mentioned in this article include KOSDAQ:A122870 KOSDAQ:A214450 and KOSE:A352820.
Do you have feedback on this article? Interested in its content? Please contact us directly. Alternatively, email us at editorial-team@simplywallst.com.
